Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study

Biomedicines

18 August Aug 2021 one month ago
  • Coggi D, Frigerio B, Bonomi A, Sansaro D, Ravani A, Ferrante P, Damigella M, Veglia F, Capra N, Tremoli E, Amato M, Baldassare D

Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key regulators of cholesterol metabolism. Despite this, its role as a player in atherosclerosis development is still matter of debate. Here, we investigated the relationships between this protein and several markers of subclinical atherosclerosis.

Reference

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study. Coggi D, Frigerio B, Bonomi A, Ruscica M, Ferri N, Sansaro D, Ravani A, Ferrante P, Damigella M, Veglia F, Capra N, Lupo MG, Macchi C, Savonen K, Silveira A, Kurl S, Giral P, Pirro M, Strawbridge RJ, Gigante B, Smit AJ, Tremoli E, Amato M, Baldassarre D, On Behalf Of The Improve Study Group. Biomedicines. 2021 Jul 19;9(7):841. doi: 10.3390/biomedicines9070841.

Go to PubMed